These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 22052798

  • 1. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
    Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA.
    Pediatr Blood Cancer; 2012 May; 58(5):815-8. PubMed ID: 22052798
    [Abstract] [Full Text] [Related]

  • 2. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
    Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Røtne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF.
    Cancer Res; 2009 Oct 01; 69(19):7672-80. PubMed ID: 19773430
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
    Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, Blockus H, Boylan JF, Ferreira C, Puget S, Abely M, Vassal G, Grill J, Geoerger B.
    Anticancer Drugs; 2015 Mar 01; 26(3):272-83. PubMed ID: 25486598
    [Abstract] [Full Text] [Related]

  • 4. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.
    Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, Shang S, Pavlick A, Shao Y, Darvishian F, Boylan JF, Osman I, Hernando E.
    PLoS One; 2011 Mar 01; 6(9):e25264. PubMed ID: 21980408
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
    Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ.
    J Clin Oncol; 2012 Jul 01; 30(19):2348-53. PubMed ID: 22529266
    [Abstract] [Full Text] [Related]

  • 6. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
    Wang L, Dai G, Yang J, Wu W, Zhang W.
    Med Sci Monit; 2018 Jun 14; 24():4046-4053. PubMed ID: 29899322
    [Abstract] [Full Text] [Related]

  • 7. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
    Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA.
    Cancer; 2015 Feb 01; 121(3):432-440. PubMed ID: 25250858
    [Abstract] [Full Text] [Related]

  • 8. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.
    Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA.
    Breast Cancer Res Treat; 2012 Jul 01; 134(2):495-510. PubMed ID: 22547109
    [Abstract] [Full Text] [Related]

  • 9. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.
    He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, Cai J, Higgins B, Kolinsky K, Rizzo C, Packman K, Heimbrook D, Boylan JF.
    Mol Oncol; 2011 Jun 01; 5(3):292-301. PubMed ID: 21315665
    [Abstract] [Full Text] [Related]

  • 10. Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.
    Pisklakova A, Grigson E, Ozerova M, Chen F, Sullivan DM, Nefedova Y.
    Cancer Biol Ther; 2016 May 03; 17(5):477-85. PubMed ID: 26934342
    [Abstract] [Full Text] [Related]

  • 11. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ.
    Pediatr Blood Cancer; 2010 Jul 15; 55(1):26-34. PubMed ID: 20108338
    [Abstract] [Full Text] [Related]

  • 12. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
    Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, Wang L, Liu G, Zhou C, Blattler C, Ivy SP, Oza AM.
    Gynecol Oncol; 2015 May 15; 137(2):216-22. PubMed ID: 25769658
    [Abstract] [Full Text] [Related]

  • 13. Targeting the Notch and TGF-β signaling pathways to prevent retinal fibrosis in vitro and in vivo.
    Fan J, Shen W, Lee SR, Mathai AE, Zhang R, Xu G, Gillies MC.
    Theranostics; 2020 May 15; 10(18):7956-7973. PubMed ID: 32724452
    [Abstract] [Full Text] [Related]

  • 14. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ.
    Pediatr Blood Cancer; 2012 Aug 15; 59(2):246-53. PubMed ID: 22012946
    [Abstract] [Full Text] [Related]

  • 15. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
    Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D.
    Pediatr Blood Cancer; 2014 Aug 15; 61(8):1493-6. PubMed ID: 24664981
    [Abstract] [Full Text] [Related]

  • 16. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
    Nair JS, Sheikh T, Ho AL, Schwartz GK.
    Anticancer Res; 2013 Apr 15; 33(4):1307-16. PubMed ID: 23564767
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
    De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W.
    Invest New Drugs; 2014 Aug 15; 32(4):739-45. PubMed ID: 24668033
    [Abstract] [Full Text] [Related]

  • 18. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
    Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R.
    Invest New Drugs; 2020 Oct 15; 38(5):1400-1410. PubMed ID: 31953695
    [Abstract] [Full Text] [Related]

  • 19. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma.
    Wu J, Wiegand R, LoRusso P, Li J.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun 01; 879(19):1537-43. PubMed ID: 21497565
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of RO4929097 in metastatic colorectal cancer.
    Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D.
    Eur J Cancer; 2012 May 01; 48(7):997-1003. PubMed ID: 22445247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.